Novartis data highlight efficacy of Piqray® in HR+/HER2

/PRNewswire/ -- Novartis today announced new Piqray® (alpelisib) data indicating benefit across a broad range of patient and disease characteristics as seen in...

Related Keywords

United States , San Antonio , Texas , New Jersey , East Hanover , America , Julie Masow , Jamie Bennett , Sloan Simpson , Prnewswire Novartis , Virtual Scientific Program , Twitter , Novartis , Exchange Commission , Novartis Pharmaceuticals , Novartis Pharmaceuticals Corporation , Nj Novartis Pharmaceuticals Corporation , Cancer Genome Atlas Network , University Of California San Francisco , Novartis Pharmaceuticals Corp , Helen Diller Family Comprehensive Cancer Center , Antonio Breast Cancer Symposium , Breast Oncology , Clinical Trials Education , California San Francisco , Helen Diller Family Comprehensive Cancer , Scientific Program , Prescribing Information , Advanced Breast , Pharmaceuticals Corporation , San Antonio Breast Cancer Symposium , Cancer Genome Atlas , Aromatase Inhibitor Resistance , Circulating Tumour , Metastatic Breast , Alpelisib Plus Fulvestrant , Participants With , Advanced Breast Cancer After Treatment With , Aromatase Inhibitor , Study Assessing , Subjects With Advanced , Carry Either , Two Part , Placebo Controlled Study , Combination With Trastuzumab , Maintenance Therapy , Patients With , Advanced Breast Cancer With , Alpelisib Plus Olaparib , High Grade Serous Ovarian Cancer ,